Cardiol Therapeutics (CRDL) Fundamental Analysis: Revenue, Earnings & Valuation

4.52 / 10

Netural

Fundamental assessment rates CRDL at 4.5/10, indicating average health. Strengths include a strong interest coverage ratio, favorable Revenue‑MV and solid inventory turnover. Weak points are high current‑liabilities‑to‑total‑liabilities, low PB‑ROE and negative Asset‑MV, suggesting liquidity and valuation concerns.

Analysis Checks(7/10)

Revenue-MV

Value-0.28

Score3/3

Weight98.69%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value78.03

Score2/3

Weight1.36%

1M Return0.13%

Inventory turnover ratio

Value47.95

Score2/3

Weight-11.25%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value97.13

Score0/3

Weight-41.70%

1M Return-4.96%

PB-ROE

Value5.76

Score0/3

Weight33.25%

1M Return2.74%

Long-term debt to working capital ratio (%)

Value0.01

Score2/3

Weight-3.49%

1M Return-0.35%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-11.44%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value92.19

Score2/3

Weight0.55%

1M Return0.05%

Cost of sales ratio (%)

Value70.31

Score2/3

Weight-10.81%

1M Return-1.13%

Asset-MV

Value-0.49

Score0/3

Weight44.85%

1M Return4.00%

Is CRDL fundamentally strong?

CRDL scores 4.52/10 on fundamentals and holds a Fair valuation at present. Backed by its -155.19% ROE, 0.00% net margin, -5.93 P/E ratio, 20.29 P/B ratio, and 33.02% earnings growth, these metrics solidify its Netural investment rating.